Last reviewed · How we verify
Tenofovir Disoproxil Fumarate and Emtricitabine
Tenofovir Disoproxil Fumarate and Emtricitabine is a Small molecule drug developed by Asociación Civil Impacta Salud y Educación, Peru. It is currently FDA-approved. Also known as: TRUVADA tablets, Truvada tablets.
At a glance
| Generic name | Tenofovir Disoproxil Fumarate and Emtricitabine |
|---|---|
| Also known as | TRUVADA tablets, Truvada tablets |
| Sponsor | Asociación Civil Impacta Salud y Educación, Peru |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (PHASE3)
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2, PHASE3)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Antiviral Clinical Trial for Long Covid-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir Disoproxil Fumarate and Emtricitabine CI brief — competitive landscape report
- Tenofovir Disoproxil Fumarate and Emtricitabine updates RSS · CI watch RSS
- Asociación Civil Impacta Salud y Educación, Peru portfolio CI
Frequently asked questions about Tenofovir Disoproxil Fumarate and Emtricitabine
What is Tenofovir Disoproxil Fumarate and Emtricitabine?
Tenofovir Disoproxil Fumarate and Emtricitabine is a Small molecule drug developed by Asociación Civil Impacta Salud y Educación, Peru.
Who makes Tenofovir Disoproxil Fumarate and Emtricitabine?
Tenofovir Disoproxil Fumarate and Emtricitabine is developed and marketed by Asociación Civil Impacta Salud y Educación, Peru (see full Asociación Civil Impacta Salud y Educación, Peru pipeline at /company/asociaci-n-civil-impacta-salud-y-educaci-n-peru).
Is Tenofovir Disoproxil Fumarate and Emtricitabine also known as anything else?
Tenofovir Disoproxil Fumarate and Emtricitabine is also known as TRUVADA tablets, Truvada tablets.
What development phase is Tenofovir Disoproxil Fumarate and Emtricitabine in?
Tenofovir Disoproxil Fumarate and Emtricitabine is FDA-approved (marketed).
Related
- Manufacturer: Asociación Civil Impacta Salud y Educación, Peru — full pipeline
- Also known as: TRUVADA tablets, Truvada tablets
- Compare: Tenofovir Disoproxil Fumarate and Emtricitabine vs similar drugs
- Pricing: Tenofovir Disoproxil Fumarate and Emtricitabine cost, discount & access